ID: ALA223531

Max Phase: Preclinical

Molecular Formula: C15H24N2O5

Molecular Weight: 312.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O

Standard InChI:  InChI=1S/C15H24N2O5/c1-2-3-4-5-6-10-8-17(15(21)16-14(10)20)13-7-11(19)12(9-18)22-13/h8,11-13,18-19H,2-7,9H2,1H3,(H,16,20,21)/t11-,12+,13+/m0/s1

Standard InChI Key:  DZGIFYLUHQAETO-YNEHKIRRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 312.37

Molecular Weight (Monoisotopic): 312.1685

AlogP: 0.30

#Rotatable Bonds: 7

Polar Surface Area: 104.55

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.95

CX Basic pKa:

CX LogP: 1.10

CX LogD: 1.10

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.63

Np Likeness Score: 0.89

References

1. Bères J, Bentrude WG, Balzarini J, De Clercq E, Otvös L..  (1986)  Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.,  29  (4): [PMID:3959027] [10.1021/jm00154a012]

2. De Clercq E, Descamps J, Balzarini J, Giziewicz J, Barr PJ, Robins MJ..  (1983)  Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.,  26  (5): [PMID:6302254] [10.1021/jm00359a008]

3. Helguera AM, Rodríguez-Borges JE, García-Mera X, Fernández F, Cordeiro MN..  (2007)  Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.,  50  (7): [PMID:17341060] [10.1021/jm061445m]

4. PubChem BioAssay data set, 

Source

Source(2):

• Scientific Literature
• PubChem BioAssays